Base Pair Biotechnologies, Inc. Industries
-
Medical / Health Care
-
-
-
As targeted therapies evolve and the limitations of antibody-based therapies become clearer, a growing number of research teams are exploring the therapeutic potential of aptamers.
In many therapeutic areas, current treatments involve significant side effects. Combining drug compounds with affinity agents that target specific cell surface receptors can dramatically reduce off-target effects and improve treatment effectiveness. In several studies, aptamer-mediated drug delivery has reduced toxicity and improved drug performance.
More than 5 million people in the United States and an estimated 50 million people worldwide are living with Alzheimer’s disease. More than 10 million people worldwide are living with Parkinson’s. Brain tumors and tumors of the central nervous system are the most common form of cancer in children under 19 and the leading cause of cancer-related deaths in children under 14 in the U.S. While antibody drugs have made great strides in cancer therapies, crossing...
Aptamers are short strands of DNA or RNA with unique secondary and tertiary structures that enable highly selective binding to various types of targets. While aptamers are similar to antibodies in their ability to specifically bind with high affinity, there are some key differences between antibodies and aptamers which have prompted an increase in aptamer development projects. Several hot areas for aptamers, along with specific aptamer advantages, are outlined...